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Summary
 
To examine the role of germinal centers (GCs) in the generation and selection of high affinity
antibody-forming cells (AFCs), we have analyzed the average affinity of (4-hydroxy-3-nitro-
phenyl)acetyl (NP)-specific AFCs and serum antibodies both during and after the GC phase of
the immune response. In addition, the genetics of NP-binding AFCs were followed to monitor
the generation and selection of high affinity AFCs at the clonal level. NP-binding AFCs gradu-
ally accumulate in bone marrow (BM) after immunization and BM becomes the predominant
locale of specific AFCs in the late primary response. Although the average affinity of NP-spe-
cific BM AFCs rapidly increased while GCs were present (GC phase), the affinity of both BM
AFCs and serum antibodies continued to increase even after GCs waned (post-GC phase). Af-
finity maturation in the post-GC phase was also reflected in a shift in the distribution of so-
matic mutations as well as in the CDR3 sequences of BM AFC antibody heavy chain genes.
Disruption of GCs by injection of antibody specific for CD154 (CD40 ligand) decreased the
average affinity of subsequent BM AFCs, suggesting that GCs generate the precursors of high
affinity BM AFCs; inhibition of CD154-dependent cellular interactions after the GC reaction
was complete had no effect on high affinity BM AFCs. Interestingly, limited affinity matura-
tion in the BM AFC compartment still occurs during the late primary response even after treat-
ment with anti-CD154 antibody. Thus, GCs are necessary for the generation of high affinity
AFC precursors but are not the only sites for the affinity-driven clonal selection responsible for
the maturation of humoral immune responses.
 
E
 
arly in the course of infection, protection is achieved
more effectively by preexisting neutralizing serum an-
tibodies than by the later set of antibodies secreted upon re-
stimulation of memory B cells (1). After infection or vacci-
nation, neutralizing serum antibodies can be detected in
humans for several decades (2, 3); immunized mice main-
tain neutralizing antibodies for more than one year. Partic-
ularly in situations of rapid and severe pathogenesis, these
long-lasting antibodies can provide a powerful mechanism
for protection against infection, morbidity, and mortality (1).
One of the characteristics of long-lasting serum antibody
is a progressive increase in affinity for the immunogen over
time, through a process called affinity maturation (4, 5). Af-
ter the introduction of hybridoma technology, it was re-
vealed that affinity maturation of serum antibody is achieved
by two key events: the generation of antibody variants by
V(D)J hypermutation and the subsequent selection of those
variants that have high affinity for antigen (6, 7). Over
time, these events lead to the preferential accumulation of
antibody-forming cells (AFCs)
 
1
 
 that secrete antibodies with
higher affinities and faster on-rates (8–10). It is widely be-
lieved that inter- and intraclonal competition for the anti-
gen retained on the follicular dendritic cells of germinal
centers (GCs; 11–13) is the basic mechanism that promotes
the selective accumulation of high affinity memory B cells
and AFCs over time (5). However, little is known about the
cellular and molecular mechanisms underlying this selection.
After immunization with T cell–dependent antigens, an-
tigen-responsive B cells in the spleen accumulate and pro-
liferate in the margins of the T cell zones, or the periarteriolar
lymphoid sheaths (PALS), and enter into two developmen-
tal pathways. B cells can either remain to form foci of AFCs
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at the margin of the PALS, or can return to the lymphoid
follicle to establish GCs (14–16). The early foci of AFCs
mainly produce low affinity antibodies encoded by germ-
line genes (17, 18). These AFCs peak in number at days 8–10
after immunization and then rapidly decline to basal levels
(16, 19). Concomitantly, AFCs in the bone marrow (BM)
start to appear around day 10 and gradually accumulate
during the late primary response (19–21). As a result, a few
months after immunization the great majority of antigen-
specific AFCs are present in BM. Since serum antibodies
have relatively short half-lives (22), it is now accepted that
the long-lived BM AFCs are responsible for long-lasting
serum antibody titers (23). Thus, cellular events leading to
the preferential accumulation of high affinity AFCs in BM
are key elements in the affinity maturation of serum anti-
body and are crucial for protective immunity. 
The GC has been identified as a site for the generation of
high affinity antibody variants through antigen-driven V(D)J
hypermutation and clonal selection (24–27). Lymphocytes
in the GC regain many characteristics of those present in
primary lymphoid tissues (28–32), including high sensitiv-
ity to antigen receptor–mediated death (28–31), consistent
with the idea that GCs are specialized sites for clonal selec-
tion. Previous reports also suggest that BM AFCs are de-
rived from GC B cells (33–35), implying that GCs are sites
for the generation and selection of high affinity BM AFCs.
However, it remains unclear to what extent mutation and
selection occur exclusively in GCs (36, 37). Recently,
Smith et al
 
.
 
 (35) showed that high affinity B cells migrate
into the BM to become AFCs during the primary GC re-
action and concluded that the frequency of high affinity
AFCs in BM quickly plateaus. These results suggest that the
GC alone is necessary and sufficient for the generation of
high affinity BM AFCs. In seeming contradiction to these
findings, the affinity maturation of serum antibody is
known to develop slowly during the first 3 wk after immu-
nization; indeed, the majority of affinity maturation in se-
rum antibody takes place after day 30 of the primary re-
sponse (38). Thus, it remains possible that affinity-driven
selection takes place in the post-GC environment. This
notion is also compatible with the previous observations
that clonal selection in each GC takes place independently
(17) and that low affinity B cells can survive the selection
process within GCs lacking high-affinity competitor B cells
(Dal Porto, J.M., A.M. Haberman, D.M. Cerasoli, M.J.
Shlomchik, and G. Kelsoe, manuscript submitted for publi-
cation)
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 and move into the memory B cell pool (35).
To understand better the mechanisms of affinity matura-
tion of serum antibody, we have used the clonally restricted
antibody response of C57BL/6 mice to the (4-hydroxy-3-
nitrophenyl)acetyl (NP) hapten (39–42) to investigate the
role of GCs in the generation and selection of long-lived,
high affinity AFCs in BM. Here, we show that the genera-
tion of high-affinity precursors of BM AFCs by somatic
mutation is totally dependent on the GC reaction, since the
frequency of H chain V(D)J mutations present in BM
AFCs increased only while GCs were present in the spleen,
and the appearance of high affinity BM AFCs could be
blocked significantly by the disruption of GCs with anti-
CD154 (CD40 ligand) antibody. However, the subsequent
selection for higher affinity AFCs does not require GCs,
and affinity-based selection among BM AFCs continues
long after the end of the GC reaction.
 
Materials and Methods
 
Antigens and Antibodies. 
 
Succinic anhydride esters of NP
were reacted with chicken-
 
g
 
-globulin (CG; Sigma Chemical
Co., St. Louis, MO) or BSA (U.S. Biochemical Corp., Cleve-
land, OH) as previously described (16). The coupling ratio of
each conjugate was determined spectrophotometrically. Normal
hamster IgG was purchased from Pierce Chemical Co. (Rock-
ford, IL). Monoclonal antibodies specific for mouse CD154 (MR1),
IgM
 
b
 
 (AF6-78), and 
 
l
 
1 L chain (Ls136) were purified over pro-
tein G–Sepharose (Pharmacia Biotech AB, Uppsala, Sweden)
from culture supernatants of each hybridoma. Horseradish per-
oxidase (HRP)–conjugated goat anti–mouse IgG
 
1
 
 and alkaline
phosphatase–conjugated anti–mouse IgM antibodies were pur-
chased from Southern Biotechnologies, Associates (Birmingham,
AL). Anti-Fc
 
g
 
RI/RII (2.4G2), FITC-labeled GL-7, PE-con-
jugated anti-B220, biotinylated anti–Mac-1, biotinylated anti–
Gr-1, biotinylated anti-Thy1.2, and PE-conjugated anti-CD138
(syndecan) antibodies were purchased from PharMingen (San Di-
ego, CA).
 
Immunizations.
 
C57BL/6 mice were immunized intraperito-
neally with 50 
 
m
 
g of NP
 
20
 
–CG conjugate precipitated in alum.
Anti-CD154 antibody or normal hamster IgG was administered
intravenously on days 6, 8, and 10, days 10, 12, and 14, or days
16, 18, and 20 after primary immunization, with 300 
 
m
 
g of anti-
body per each injection.
 
Enzyme-linked Immunospot.
 
The frequency of NP-specific
AFCs from both splenocytes and BM cells was estimated by en-
zyme-linked immunospot (ELISPOT) using two different cou-
pling ratios of NP–BSA. Nitrocellulose filters were coated with
50 
 
m
 
g/ml NP
 
5
 
–BSA, NP
 
26
 
–BSA, or BSA in PBS at 4
 
8
 
C over-
night, and then blocked with 1% BSA in PBS. Splenocytes (10
 
5
 
cells/well) or BM cells (5 
 
3 
 
10
 
5
 
 cells/well) were incubated on
the nitrocellulose filters in 96-well plates at 37
 
8
 
C, 5% CO
 
2
 
. After
a 2-h incubation, nitrocellulose filters were washed with PBS
containing 50 mM EDTA once, followed by PBS containing
0.1% Tween 20 (Sigma Chemical Co.) twice and PBS once. Fil-
ters were double-stained with alkaline phosphatase–conjugated
anti-IgM and HRP-conjugated anti-IgG
 
1
 
 antibodies. Alkaline
phosphatase and HRP activities were visualized using 3-amino-
ethyl carbozole and napthol AS-MX phosphate/fast blue BB (Sigma
Chemical Co.), respectively, as previously described (16). The
frequency of high affinity and total AFCs was determined from
NP
 
5
 
–BSA– and NP
 
26
 
–BSA–coated filters after background on
BSA-coated filters was subtracted.
Several J558L myeloma lines (H
 
2
 
; 
 
l
 
1
 
1
 
) transfected with an
Ig
 
g
 
1 expression vector carrying different VDJ rearrangements de-
rived from NP-binding B cells
 
2
 
 were incubated at 100 cells/well
on nitrocellulose filters coated with these NP–BSA conjugates to
determine the threshold of antibody affinity which can be de-
tected by each NP–BSA conjugate. Transfectomas secreting NP-
binding antibody with an association constant (
 
K
 
a
 
)
 
 
 
5 
 
2.0 
 
3 
 
10
 
7
 
2
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M
 
2
 
1 
 
(H33L
 
g
 
1/
 
l
 
1) could be detected by both NP
 
5
 
–BSA and
NP
 
26
 
–BSA. However, transfectomas with a 
 
K
 
a
 
 5 
 
10
 
6
 
 M
 
2
 
1
 
 could
be detected by NP
 
26
 
–BSA, but not by NP
 
5
 
–BSA. Transfectomas
with a 
 
K
 
a
 
 5 
 
2.3 
 
3 
 
10
 
5
 
 M
 
2
 
1
 
 could not be detected by either NP–
BSA coat. Thus, AFCs secreting antibody with a 
 
K
 
a
 
 >
 
2.0 
 
3 
 
10
 
7
 
M
 
2
 
1
 
 can be detected with NP
 
5
 
–BSA, and those with a 
 
K
 
a
 
 >
 
10
 
6
 
M
 
2
 
1
 
 can be detected with NP
 
26
 
–BSA.
 
Measurement of Serum IgG
 
1
 
 or 
 
l
 
1 Antibody.
 
IgG
 
1
 
 or 
 
l
 
1 anti-
body specific for the NP hapten was detected by ELISA using
two different coupling ratios of NP–BSA as the coating antigens.
In brief, 96-well flat bottom plates (Falcon; Becton Dickinson,
Oxnard, CA) were coated with 50 
 
m
 
g/ml NP
 
5
 
–BSA or NP
 
26
 
–
BSA in 0.1 M carbonate buffer (pH 9.0) at 4
 
8
 
C overnight, and
blocked with 0.5% BSA in carbonate buffer. Serially diluted sera
were then added to each well and incubated at 4
 
8
 
C overnight.
On each plate, serially diluted H33L
 
g
 
1/
 
l
 
1, a monoclonal anti-
body recognizing the NP hapten (
 
K
 
a
 
 5 
 
2.0 
 
3 
 
10
 
7
 
 M
 
2
 
1
 
)
 
2
 
 was also
included as a control. After washing with PBS containing 0.1%
Tween 20, HRP-conjugated goat anti–mouse IgG
 
1
 
 or biotiny-
lated Ls136 was added and incubated at room temperature for 2 h.
HRP-conjugated streptavidin was added to detect biotinylated
Ls136; HRP activity was visualized using a TMB peroxidase sub-
strate kit (Bio-Rad Laboratories, Hercules, CA) and optical den-
sities were determined at 450 nm. The concentrations of anti-NP
IgG
 
1
 
 or 
 
l
 
1 antibodies were estimated by comparison to standard
curves created from the H33L
 
g
 
1/
 
l
 
1 control on each plate. To
estimate the affinity of NP-binding antibody in the sera, the ratio
of NP
 
5
 
-binding antibody to NP
 
26
 
-binding antibody was calcu-
lated (43).
The affinity threshold of antibody binding to each NP–BSA
conjugate was determined by using several monoclonal antibodies
with different affinities for NP. H33L
 
g
 
1/
 
l
 
1 bound equally well
to both NP–BSA conjugates, whereas a monoclonal antibody with
a 
 
K
 
a
 
 5 
 
10
 
6
 
 M
 
2
 
1
 
 showed a 20-fold lower binding to NP
 
5
 
–BSA
than to NP
 
26
 
–BSA. A monoclonal antibody with a 
 
K
 
a
 
 5 
 
2.3 
 
3 
 
10
 
5
 
M
 
2
 
1
 
 had a 10-fold lower binding to NP
 
26
 
–BSA than one with a
 
K
 
a
 
 5 
 
1.0 
 
3 
 
10
 
6
 
 M
 
2
 
1
 
. Thus, antibody with a 
 
K
 
a
 
 >
 
2.0 
 
3 
 
10
 
7
 
 M
 
2
 
1
 
can be detected with NP
 
5
 
–BSA, and one with a 
 
Ka >106 M21
can be detected with NP26–BSA.
Flow Cytometry. Single cell suspensions of splenocytes and
BM cells were prepared and RBCs were depleted by incubation
in 0.83% NH4Cl; cells were then washed with PBS (pH 7.4) con-
taining 2% FCS and 0.08% sodium azide at 48C for cytometric
analysis, or washed with deficient RPMI 1640 (Irvine Scientific,
Santa Ana, CA) containing 2% FCS for sorting. To estimate the
prevalence of GC B cells, cells were stained with FITC-labeled
GL-7, PE-conjugated anti-B220, and 7-aminoactinomycin D
(7-AAD; Molecular Probes, Inc., Eugene, OR) for 30 min after
incubation with anti-FcgRI/RII for 10 min to block FcgR-
mediated binding. After washing three times, .30,000 events
were collected on a FACSortÒ machine (Becton Dickinson,
Mountain View, CA) and the percentage of GL-71, B2201 cells
were calculated from live lymphocytes selected by forward-side
scatter pattern and exclusion of 7-AAD, using CellQuest software
(version 3.01; Becton Dickinson).
To collect BM AFCs, BM cells pooled from four or five mice
were blocked with anti-FcgRI/RII and then stained with bioti-
nylated anti-IgMb, –Mac-1, –Gr-1, and –Thy1.2 antibodies for
30 min. After three washes, cells were incubated with streptavi-
din-conjugated microbeads (Miltenyi Biotec, Gladbach, Ger-
many) for 15 min. Cells attached to microbeads were depleted by
passage through a CS column (Miltenyi Biotec) in a magnetic
field based on the manufacturer’s protocol. Recovered cells were
stained with FITC-labeled Ls136, PE-conjugated anti-CD138,
Tricolor-conjugated streptavidin (Caltag Laboratories, South San
Francisco, CA), and 7-AAD. Finally, l11, CD1381 cells within
the Tricolor2 (IgMb2, Mac-12, Gr-12, Thy1.22), 7-AAD2 frac-
tion (routinely between 0.003 and 0.015% of cells) were sorted
into Trizol (GIBCO BRL, Gaithersburg, MD) containing 50
mg/ml tRNA (Escherichia coli; Boehringer Mannheim, Indianapo-
lis, IN) at 50–200 cells per tube using a FACStar PlusÒ (Becton
Dickinson). Sorting routinely yielded populations of .90% purity.
Affinity Measurement of Serum Antibody by Fluorescence Quench-
ing. In addition to differential ELISAs, the affinity of anti-NP
serum antibody was estimated by fluorescence quenching (44).2
In brief, serum IgG was purified from cohorts of mice using pro-
tein G–Sepharose and adjusted to a concentration of 50 mg/ml in
2 ml of PBS containing 0.02% Tween 20. Titrations were carried
out by adding monovalent NP hapten (NP-caproate; Genocys,
Woodlands, TX) over a three-log molar range (1028–1025). For
the correction of nonspecific quenching, quenching from an ir-
relevant antibody, a mouse anti-dextran IgG1 (MOPC 21; Sigma
Chemical Co.), was also determined.
Sequence Analysis of VDJ DNA from BM AFCs. Total RNA was
extracted from sorted, Trizol-solublized BM AFCs based on manu-
facturer’s protocol. First strand cDNA was synthesized from total
RNA using a primer complementary to the CH1 region of Cg1
(Cg1 primer; 59-GAGTTCCAGGTCACTGTCACTGGCTCA-
GGGA-39) and a Superscript Kit (GIBCO BRL). 5 ml of cDNA
solution was used as a template for two rounds of nested PCR to
amplify VH genes combined to the Cg1 region. PCR amplifica-
tion, cloning, and sequencing of VH genes were performed as
previously described (24, 30), except that the Cg1 primer was
used as an antisense primer for the first round of PCR amplifica-
tion. This PCR scheme minimizes any contribution of VDJ rear-
rangements from immature BM B cells to the data set.
Results
Primary Immunization with NP–CG Induces Long-lasting
Serum Antibody and High Frequencies of Specific AFCs in
BM.  After primary immunization with 50 mg of NP–CG,
the number of splenic AFCs secreting NP-specific, IgG1
antibody peaked at day 8 after immunization and then rap-
idly declined (Fig. 1 A). Concomitantly, the number of
BM AFCs slowly grew, such that by 4 mo after immuniza-
tion the frequency of hapten-specific AFCs in the BM was
.10-fold higher than in the spleen. The increased fre-
quency and persistence of NP-specific AFCs in the BM
correlated with persistent titers of NP-binding IgG1 anti-
body in the serum (Fig. 1 B). Maximum levels of circulat-
ing antibody (900–1700 mg/ml) were observed at day 12
after immunization. Circulating antibody concentrations then
declined to z50% of this peak and remained stable from
day 32 to day 119 after immunization. Combined with the
relatively short half-life of circulating antibody (22) and the
prominent role of BM in long-term antibody production
(20, 21), persistent IgG1 serum antibody appears to be the
product of BM AFCs.
The near exclusive use of l1 L chain in NP-binding an-
tibody during the early primary response is diminished in
secondary responses which support increased percentages
of k-bearing, NP-specific antibody (20–40%; references888 Clonal Selection in the Post–germinal Center Environment
40, 45). To estimate the stability of l1 expression among
persistent IgG1 antibody, both the l1 and the IgG1 anti-
body titer in each sera was calculated by ELISA using the
same control antibody bearing IgG1/l1. As shown in Table
1, the percentage of l1/IgG1 remained above 80% from
day 46 to day 119 after immunization. Thus, no significant
replacement by NP-specific antibody-bearing k L chain
was observed.
Kinetics of the Primary GC Response. To quantitate the
GC reaction over the course of a primary humoral re-
sponse, we determined the frequency of splenic GL-71
B2201 GC B cells by flow cytometry (32) at days 12, 22,
32, 46, and 69 after immunization with NP–CG (Fig. 2).
Confirming our histologic determinations (16), GC B cells
increased from background levels of 0.4 6 0.3% (average 6
SD) to a peak of 2.3 6 0.6% at day 12 after immunization.
Subsequently, the GC reaction quickly waned; at day 22 of
the response the frequency of GC B cells fell to 1.1 6
0.4%, reaching naive levels by day 32. Thus, the primary
antibody response (Fig. 1) continues long after the GC re-
action can no longer be detected (Fig. 2).
The Average Affinity of BM AFCs and Serum Antibody In-
creases after GCs become Undetectable. The average affinity
of AFCs from both spleen and BM was estimated by calcu-
lating the ratios of AFCs enumerated on ELISPOT sub-
strates with sparse (high affinity AFC) or abundant (low
and high affinity AFC) levels of NP hapten (Fig. 3). This
assay was validated with cells secreting NP-specific mono-
clonal antibodies with different affinities for NP (data not
shown). To be detected on the NP5–BSA substrate, AFC
had to secrete antibody with a Ka >2.0 3 107 M21; AFC
secreting antibody with 20-fold lower affinity could be de-
tected only on NP26–BSA. The ratio of high affinity versus
total NP-binding AFCs in BM rapidly increased from
29.2% to 51.5% while GC B cells were present in the
spleen (Fig. 2), and later continued a more gradual, but ap-
preciable increase (68.4% at day 32, 85.4% at day 119; P ,
0.05, Student’s t test) after the GC response became unde-
tectable. The average affinity of NP-binding serum antibody
was also determined in the same mice by ELISA (Fig. 4 A)
and fluorescence quenching (Fig. 4 B). Mirroring affinity
Figure 1. Kinetics of NP-binding IgG1 AFCs and serum IgG1 antibody
elicited by primary immunization with NP–CG. Numbers of NP-bind-
ing AFCs from BM (open circles) and spleen (filled circles) were determined
by ELISPOT using NP26–BSA as the capture antigen (A). NP-binding se-
rum antibody was determined by ELISA using NP26–BSA (B). The data
represent the mean 6 SD from three to nine individual mice per time
point.
Table 1. Continued Predominance of l11 Antibody in the 
Primary Anti-NP Response
Days after
immunization NP-binding primary antibody
Average concentration
mg/ml Percent l11
(average 6 SD) l11 g11
22 (n 5 4) 1,249 1,082 116 6 5
32 (n 5 5) 753 637 120 6 18
46 (n 5 4) 513 581 90 6 13
69 (n 5 6) 296 369 82 6 9
119 (n 5 4) 395 467 91 6 12
Figure 2. Kinetics of the primary GC response. The percentage of GC
B cells out of live lymphocytes was assessed by co-staining with anti-B220
and GL-7 antibodies. The data represent the average number and standard
deviation from individual mice (n 5 3–9). The background staining with
these antibodies was determined from naive mice, and is indicated (along
with SD) by the hatched area. *, **: Staining that is statistically different
from background at P ,0.001 and P ,0.005, respectively, using the stu-
dent’s t test.889 Takahashi et al.
increases in BM AFCs, the average affinity of serum anti-
body also increased from day 12 to day 119 of the response
(Fig. 4). Indeed, the majority of affinity maturation in the
serum antibody took place after day 32, when GC B cells
could no longer be detected in the spleen. The different
pattern of increase in affinity between BM AFCs and serum
antibody (Figs. 3 and 4) is likely to be due to the rate of de-
cay (half-life) of serum IgG1 antibody. Together, these data
suggest that antigen-driven clonal selection for high affinity
BM AFCs or their precursors continues in the post GC en-
vironment.
Affinity Maturation of Serum Antibody Is Reflected in the So-
matic Genetics of the BM AFC Population. Initially, NP–CG
activates a diverse population of splenic B cells that bear the
l1 L chain (39, 40) and H chain genes containing members
of the V186.2 and V3 subfamilies of J558 VH gene segments
C1H4, V23, CH10, V186.2, 24.8, or 165.1 (46, 47). With
time, interclonal competition (47)2 leads to the predomi-
nance of higher affinity cells carrying V186.2-to-DFL16.1
rearrangements with a tyrosine-rich junctional motif, YYGS
(42, 48) and an affinity-enhancing W®L mutation at posi-
tion 33 (35, 49, 50).
To follow clonal competition and selection in BM
AFCs, we enriched this population by depleting IgM1, Gr-
11, Mac-11, and Thy1.21 cells from BM and we then pu-
rified  l11, CD1381 cells by fluorescence-activated cell
sorting. Typically, .40% of this population secreted NP-
binding, IgG1 antibody by ELISPOT. Enriched BM AFC
populations obtained at days 12, 46, and 119 after immuni-
zation were subjected to a reverse transcriptase PCR that
preferentially amplifies cDNA representing rearrangements
of the V186.2 and V3 subfamilies of J558 VH gene seg-
ments joined to Cg1. Cloned VDJ segments from each
time point (n: day 12 5 18; day 46 5 31; day 119 5 22)
were then sequenced to follow the somatic genetics of the
BM AFC population over the course of the primary re-
sponse.
Table 2 summarizes these data and shows that clonal
dominance by IgG1 B cells expressing V186.2-to-DFL16.1
rearrangements takes place in the BM, albeit at a slower
pace than reported for the splenic compartment. At day 12,
some 78% of the VDJ rearrangements amplified from
sorted  l11 BM AFCs contained the V186.2 gene segment;
fewer than half of these (43%) were rearranged to DFL16.1
and none contained the YYGS motif in CDR3. However,
with time the frequency of canonical V186.2 rearrange-
ments increased; by day 119 only V186.2 rearrangements
were recovered and the great majority of these (91%) were
fused to DFL16.1. Almost half (41%) of the VDJ fragments
from day 119 BM AFCs encoded YYGS at the V-to-D
junction (Table 2).
Mutations in transcribed VDJ rearrangements accumu-
lated in BM AFCs, reaching a maximum average of 4.6
mutations per VH gene segment by day 119 after immuni-
zation (Table 2). The apparent increase in VH mutations
was most rapid in the earliest phase of the response. Indeed,
the rate of accumulated mutations in the first 12 d of the
Figure 3. The average affinity of NP-binding IgG1 BM AFCs increases
after GCs become undetectable. The frequency of NP5-binding and
NP26-binding IgG1 AFCs from BM was determined by ELISPOT. The
ratios of NP5-binding versus NP26-binding AFCs were then plotted as
shown. Each point represents an individual mouse.
Figure 4. The average affinity of NP-binding IgG1 antibody in the se-
rum continues to increase after GCs become undetectable. The average
affinity of serum antibodies at different time points was estimated by
ELISA (A) and fluorescence quenching (B). (A) The concentrations of
NP5-binding and NP26-binding IgG1 antibody were determined by
ELISA and the ratios of NP5 versus NP26-binding IgG1 antibody were
plotted. Each dot represents the result from an individual mouse. (B) The
Ka of IgG serum antibody against a monovalent form of NP hapten was
determined by fluorescence quenching. Sera was pooled from two to four
mice of each group and IgG antibody was purified by passing through a
protein G–Sepharose column. The data represent the mean 6 SD from
two independent serum pools. 890 Clonal Selection in the Post–germinal Center Environment
response is 11-fold greater than that observed late (days 47–
119) in the response (0.17 versus 0.016 VH mutations per
day). The frequency of silent mutations present in BM
AFCs did not increase after day 46. Together, these obser-
vations suggest that most, if not all, VH mutations present in
mature populations of IgG1 BM AFCs were introduced
during the first 30 d of the response.
The changing distribution and frequency of specific VH
mutations in BM AFCs, like the eventual dominance of ca-
nonical VDJ rearrangements, suggests affinity-driven selec-
tion in the BM compartment. On average, the ratio of
replacement/silent mutations was suppressed in the frame-
work regions of mutated VH genes. More significantly, the
frequency of W®L mutations in codon 33 increased from
0% at day 12 after immunization to a maximum of 25% by
day 46 (Table 2).
Disruption of GCs Selectively Inhibits the Appearance of High
Affinity BM AFCs and Impairs Affinity Maturation of Serum
Antibody. To elucidate the role of the GC reaction in the
production of high affinity BM AFCs, we created GC-
deficient mice by injecting them with the anti-CD154
(CD40 ligand) monoclonal antibody, MR1 (51). MR1-
treatment after initiation of primary anti-NP responses re-
sults in complete disruption of nascent GCs without inhib-
iting the splenic foci of AFCs or early serum antibody titers
(30, 52). Previous histological studies (16) and Fig. 2 dem-
onstrate that splenic GCs appear by day 4–6 after immuni-
zation and reach peak cell numbers per volume by day 12–
16. The primary GC reaction then declines to basal levels
by day 32 after immunization (53) (Fig. 2). In this study,
administration of MR1 antibody was conducted on three
different schedules: days 6, 8, and 10 (early schedule),
which permitted GCs to be formed but permitted little or
no clonal selection; days 10, 12, and 14 (intermediate
schedule), which allowed GCs to support the initiation of
V(D)J hypermutation and selection; and days 16, 18, and
20 (late schedule), which was permissive for extensive mu-
tation and selection. 2 d after the final MR1 treatment, his-
tological staining of spleen sections with peanut agglutinin
and enumeration of GL-71 B2201 splenocytes by flow cy-
tometry were performed to confirm that splenic GCs were
no longer present. In all experiments, administration of
MR1 antibody resulted in the complete loss of splenic GC
Table 2. Somatic Genetics of l11 AFC in BM of C57BL/6 
Mice Immunized with NP–CG
V186.2 (%)
Other (%)
d12 d46 d119
78
22
90
10
100
0
V186.2 mutation frequency 2.0 3.4 4.6
(n 5 14) (n 5 28) (n 5 22)
R/S ratio
CDR1 (14.0/1)* .1.0/1 1.2/1 .9.0/1
CDR2 (4.3/1) .4.0/1 10.0/1 3.8/1
FW (3.1/1) 2.3/1 2.1/1 2.6/1
DFL16.1 (%)‡ 43 79 91
YYGS (%)§ 02 5 4 1
W ® L 33 (%)i 02 5 2 3
All sequence data are available from EmBL/GenBank/DDBJ under ac-
cession number AF028612-25 (day 12), AF028626-53 (day 46), and
AF028654-75 (day 119).
*Expected R/S ratio of VHV186.2 given random mutagenesis.
‡The percentage of rearrangements using DLF16.1 gene segments in all
rearrangements of VHV186.2.
§The percentage of rearrangements encoding YYGS in CDR3 in all
rearrangements of VHV186.2.
iThe percentage of all VHV186.2 rearrangements bearing a W®L mu-
tation in 33.
Figure 5. Disruption of GCs impairs affinity maturation of serum anti-
body due to the selective inhibition of high affinity BM AFCs. MR1
(open circles) or control antibody (filled circles) was intravenously adminis-
tered at days 6, 8, and 10 (early), days 10, 12, and 14 (intermediate), or
days 16, 18, and 20 (late). At day 69 after immunization, sera and BM
cells were recovered. Numbers of NP5-binding and NP26-binding AFCs
in BM were determined by ELISPOT (A) and the ratios of NP5-binding
versus NP26-binding AFCs were plotted (B). The amount of NP5-binding
or NP26-binding IgG1 antibody in each serum was determined by ELISA
(C) and the ratios of NP5-binding versus NP26-binding antibody were
plotted (D).891 Takahashi et al.
structures and reduction of GL-71 B2201 cell numbers to
background levels (data not shown). Mice treated with a
control hamster antibody showed no significant changes in
GC structure or cell numbers relative to untreated mice
(data not shown). The numbers of high affinity and total
NP-binding AFCs in the BM of MR1-treated mice were
determined at day 69 after immunization (Fig. 5). Injection
of MR1 antibody selectively inhibited the emergence of
high affinity BM AFCs (Fig. 5 A) and led to decreased ra-
tios of high affinity versus total NP-binding AFCs (Fig. 5
B). The MR1 antibody, but not hamster Ig, also inhibited
the production of high affinity serum antibody for NP
without suppressing the titers of lower affinity antibody
(Fig. 5 C). Inhibition of high affinity antibody was most ef-
fective when MR1 was given on the early schedule; pro-
longing the GC reaction by delaying the injection of MR1
allowed proportionate recovery of the high affinity serum
antibody (Fig. 5 D), and MR1-treatment after the GC re-
action was complete (days 46, 48, and 50) had no effect on
either high affinity BM AFCs or on serum antibody (see
below). Thus, the average affinity of serum antibody for
NP in immunized mice receiving the early schedule of pas-
sive MR1 antibody was about five times lower (Ka 5 6.1 3
105 M21) than antibody from control mice (Ka 5 2.9 3 106
M21). These data suggest that the major, if not sole, source
of high affinity cells in the BM AFC compartment is the
GC reaction. Lower affinity AFCs may represent GC emi-
grants that have not yet achieved high affinity by mutation
and/or selection.
Disruption of GCs Does Not Impair Affinity-driven Selection
of BM AFCs. Disruption of nascent GCs by the adminis-
tration of MR1 antibody at days 6, 8, and 10 after immuni-
zation suppresses the high affinity compartment of BM
AFCs and the affinity maturation of serum antibody (Fig.
5). However, affinity maturation within the small residuum
of higher affinity BM AFCs remained intact (Fig. 6). The
affinities of BM AFCs were determined on days 12, 22, and
69 after immunization with NP–CG and early MR1 treat-
ment. Consistent with results illustrated in Fig. 5, the fre-
quency of BM AFCs capable of binding NP5–BSA on days
22 and 69 was suppressed. Nonetheless, the relative fraction
of high affinity BM AFCs increased in MR1-treated mice
in parallel with control animals. This increase occurred in
the complete absence of detectable GCs or GC cells in the
spleens of MR1-treated mice. Thus, while the GC reaction
limits the extent and quality of the high affinity compart-
ment of BM AFCs, antigen-driven selection in this com-
partment is independent of GCs.
This late phase of affinity maturation is relatively inde-
pendent of CD154-mediated costimulation and thus is dis-
tinct from the earlier selection in GCs. MR1-treatment
over days 46–50 after immunization did not suppress the
number (5.1/105 versus 5.3/105) or fraction of high affinity
(81 versus 73%) BM AFCs, nor did it diminish high affinity
serum antibody responses (219 mg/ml versus 140 mg/ml).
Discussion
Affinity maturation of serum antibody is a cardinal but
poorly understood phenomenon of humoral immune re-
sponses to thymus-dependent antigens. Early studies at-
tempted to explain affinity maturation in Darwinian terms:
clonal competition for decreasing amounts of antigen selec-
tively maintains proliferation in B cells bearing the most
avid receptors (5). More recent work supports this view
and demonstrates that clonal competition is coupled to a
process of V(D)J hypermutation in GCs (24, 25). It is now
widely believed that affinity maturation is accomplished
during the GC reaction by inter- and intraclonal competition
(18, 25, 47, 54). Nonetheless, several incongruent observations
suggest that some affinity-driven selection, perhaps even most,
takes place outside of the GC microenvironment.
First, affinity maturation of serum antibody continues
long after the usual termination of primary GC responses.
As early as 1972, Davie and Paul noted a 25-fold increase
in the affinity of serum antibody (Ka 5 2.5 3 107 M21 to
6.3 3 108 M21) for the 2,4-dinitrophenyl hapten from day
45 to 171 of a primary response (38), well after the end of
most primary GC reactions (53). Another incongruent ob-
servation is that mature GCs often contain B cell popula-
tions that express receptor affinities below that of the serum
Figure 6. Disruption of GCs does not impair the process of affinity-
driven selection of BM AFCs. Mice were injected with NP-CG and
given MR1 antibody (open circles) or control Ig (filled circles) 6, 8, and 10 d
later. NP5- and NP26-binding, IgG1 AFCs in the BM of both groups were
enumerated by ELISPOT assay on days 12, 22, and 69 of the response.
Ratios of NP5- to NP26-binding AFCs were plotted; each point repre-
sents a single mouse.892 Clonal Selection in the Post–germinal Center Environment
antibody (55).2 Splenic GCs support oligoclonal lympho-
cyte populations that show no evidence for significant B
cell trafficking between GCs and thus no homogenization
of selected populations (17). Although B cells in the same
GC bear receptors with similar affinities, GCs in the same
spleen can hold B cell populations with hapten-specific af-
finities that differ by 100-fold (55 and Shimoda, M., J. Dal
Porto, and G. Kelsoe, unpublished observations). Finally,
limited affinity maturation has been observed in lympho-
toxin-a–deficient mice (37). Such mice are unable to form
splenic GCs in response to noninflammatory antigens.
To determine the extent and role of post-GC selection
in affinity maturation, we measured the affinity of hapten-
specific AFCs and serum antibody over a period of 4 mo
(119 d) after primary immunization with NP–CG. In-
creased numbers of BM AFCs were correlated with persis-
tent titers of serum antibody (Fig. 1) and both AFCs (Fig.
3) and antibody (Fig. 4) exhibited coordinated increases in
affinity for the NP hapten. This affinity maturation took
place over the entire period of study, even after the end of
the GC response in the spleen (Fig. 2).
The clonal selection responsible for increased affinity of
serum antibody and BM AFCs in the post-GC phase was
reflected in the somatic genetics of the BM AFC popula-
tion (Table 2). In concert with late affinity maturation, cells
bearing VDJ rearrangements characteristic of high affinity
anti-NP antibody, e.g., using the VHV186.2 and DFL16.1
gene segments and the YYGS motif in CDR3 (42, 48), ac-
cumulated in the BM AFC compartment. From day 46 to
119 of the response, the distribution of replacement muta-
tions shifted dramatically from CDR2 to CDR1, without
substantial increases in mutation frequencies. These changes in
the BM AFC population are best explained by interclonal
competition and selection after the GC reaction has ended.
This sequence analysis (Table 2) also suggests that the GC
reaction is the major, if not sole, source of VH mutations
present in BM AFCs. The rate of accumulation for VH mu-
tations in BM AFCs was greatest during the active GC re-
action and the maximum frequency of mutations achieved
in the BM AFC population, 4.6 per VH gene segment, did
not differ dramatically from that present in splenic GC B
cells (3.8 per VH gene segment) recovered by fluorescence-
activated cell sorting at day 16 of the response (56). Late af-
finity maturation acts upon the genetic diversity generated
early in the response; BM AFCs, perhaps even those that
are unmutated, appear to be derived from GC B cells.
This notion is supported by our use of the MR1 anti-
body to define a cell compartment responsible for the gen-
eration of high affinity BM AFCs and serum antibody (Fig.
5). Administration of this CD154-specific antibody after
day 6 of the response to NP–CG has no effect on early pri-
mary antibody titers (52), the generation of T cell help
(57), or T cell memory as determined by in vitro recall re-
sponse (data not shown). However, the MR1 antibody
does abrogate the GC reaction within hours of its injection
(52) without the induction of significant apoptosis in B
cells (30, 58). The MR1-treatment used in this study com-
pletely eliminated all splenic GCs as determined by histol-
ogy and the enumeration of GL-71 B2201 splenocytes
(data not shown); continuing surveys found no evidence
for the re-formation of GCs. Administration of MR1 anti-
body after the end of the GC reaction had no discernable
effect on NP-specific BM AFCs or serum antibody level
(data not shown). Thus, the progenitors of high affinity
BM AFCs and GC B cells share sensitivity to suppression
by the MR1 antibody during the second and third weeks
of the response.
Despite the complete loss of GCs and splenic B cells
bearing the GC phenotype, affinity maturation was present
in all mice treated with MR1 antibody. Indeed, although
disruption of CD40–CD154 interactions lowered the fre-
quency of high affinity BM AFCs and suppressed the aver-
age affinity of serum antibody, antigen-driven selection was
equally efficient in MR1-treated and control mice (Fig. 6).
Even the administration of MR1 antibody during the late
phase (days 46–50) of the primary response did not suppress
affinity maturation in the BM AFC compartment. These
results demonstrate that clonal selection among BM AFCs
is independent of the GC microenvironment and resistant
to blockade of CD154-mediated costimulation.
In contrast to a similar study by Smith et al. (35), we did
not observe an early plateau in the affinity of BM AFC.
Nor did we observe preferential, early recruitment of AFCs
carrying the affinity-enhancing W®L mutation at position
33 of the V186.2 VH gene segment (35, 49); instead, a
maximum of only one-fourth of VHV186.2 rearrangements
recovered from BM AFCs carried this exchange at days 46
and 119 after immunization (Table 2). These contradic-
tions may be due to very different experimental approaches
for the isolation of NP-binding B cells. Smith et al. deter-
mined the affinity and somatic genetics of BM AFCs only
after antigen-based selection using a fluorescent NP-hapten
(35), a process that may have biased the selected population
for high affinity. Biased selection might be heightened in
BM AFC populations, since surface Ig expression by these
cells is low (23). Instead, we enriched NP-binding BM
AFCs based on their expression of l1 and CD138. Subse-
quently, cloned cDNAs were sequenced without further
selection, such as colony hybridizations to detect CDR3
sequences typical of primary NP-specific B cells (49). Thus,
although our selection criteria limited our study to l11
cells and rearrangements of the V3 and V186.2 VH subfam-
ilies, antibody affinity and CDR3 diversity were uncon-
strained.
One might argue against the specificity of BM AFCs
collected with regard to only l1 and CD138 expression.
However, we believe that the fraction of VDJ rearrange-
ments amplified from nonspecific B cells was negligible,
since nearly one-half of the selected cells secreted NP-
binding IgG1 antibody and the majority of amplified VDJ
rearrangements contained the V186.2 gene segment despite
the ability of our PCR primers to amplify many other re-
lated VH gene segments (47, 49). Furthermore, we did not
detect l11 CD1381 cells in BM after depletion of IgM1
Mac-I1 Gr-I1 Thy1.21 cells from 8–20-wk-old naive mice
(data not shown). Thus, we propose that the relatively low893 Takahashi et al.
frequency of the W®L mutation in our study does not re-
flect contamination by large numbers of nonspecific B cells
but represents the true pattern of clonal selection in vivo
without the confounding effects of artifactual enrichment. 
In the primary response to NP–CG, affinity maturation
of the serum antibody develops in two stages of clonal se-
lection within and outside GCs. While GCs are present,
antigen-driven selection progressed rapidly but could be
halted by interrupting CD40–CD154 interactions with in-
jections of the MR1 antibody. However, even after the
GC reaction waned, affinity maturation and clonal selec-
tion continued, independent of GC structure and inhibi-
tion by MR1. Thus, the primary role for GCs in the affin-
ity maturation of serum antibody seems to be the generation
of high affinity variants by V(D)J hypermutation; after-
wards, antigen-driven interclonal selection can occur out-
side of the GC microenvironment. Long-term clonal selec-
tion in the post-GC environment offers the opportunity to
continue to improve the antigen-selected repertoire by al-
lowing direct competition between the progeny of both
high and lower affinity GC B cells. This process does not
seem to take place between the isolated B cell populations
present in different GCs, even when those populations are
separated by only 20–50 mm (16).
The important question of where and how clonal selec-
tion takes place in the post-GC environment remains un-
answered. The maintenance of memory B cells is thought
to be dependent on the presence of persistent antigen (59)
and z10% of memory B cells are still in cell cycle at day
140 after primary immunization (60). These observations
suggest that memory B cells are frequently restimulated by
antigen held on follicular dendritic cells (11–13). One pos-
sible mechanism for continued selection might be competi-
tion among memory B cells for restimulation with persis-
tent antigen. In support of this idea, it has been suggested
that BM AFCs are generated by the migration of restimu-
lated memory B cells from the spleen after secondary chal-
lenge (33, 61). In humans, B cells with memory phenotype
have been shown to accumulate in BM with age, presum-
ably as a consequence of a lifetime’s exposure to antigens
(62). If this were the case in mice, clonal selection in the
BM AFCs might represent the transition of selected, mem-
ory cells into AFCs (20, 34, 61).
However, we do not believe that restimulation of mem-
ory cells accounts for affinity maturation late in the primary
response. Recent labeling studies (23) demonstrate that the
BM AFC compartment is not sustained by the proliferation
of (memory) B lymphocytes but represents an independent,
long-lived population. Furthermore, BM AFC numbers,
affinity, and antibody production are not diminished by ad-
ministration of the MR1 antibody after the primary GC re-
action is complete. In contrast, secondary B cell responses
are highly dependent on CD154-mediated costimulation as
they are dramatically suppressed by MR1 antibody (57).
Indeed, BM AFCs may directly compete for activation by
antigen; unlike the early AFCs present in the spleen, BM
AFCs express mIg and exhibit low levels of proliferation
(23). However, the question still remains as to where the
antigen depot required for this competitive stimulation
might be located.
Although many studies have focused on memory B cells
to examine the protective role of humoral immune re-
sponses, the AFCs in the BM compartment have been rela-
tively neglected despite their significant contribution to the
maintenance and quality of serum antibody (1, 20, 23, 35,
61). Recent accumulating data suggest that BM AFCs are a
unique population distinct from the terminally differenti-
ated AFCs present in secondary lymphoid tissues. Further
studies are required to determine the contribution of these
cells to protective immunity and to understand the biology
of their selection and longevity.
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